Where Consultancy Leads and GMP Delivers. Your CGT CDMO Partner

“Quell and eXmoor have worked productively and successfully together for several years, and we are excited to extend our relationship with them to support our clinical manufacturing needs.”

“Having worked together for over a decade, eXmoor’s deep expertise and hands-on support were essential in bringing our first Treg product into clinical trials. From process development strategy to GMP manufacturing readiness, their team provided critical training, operational support, and facility qualification—helping us bridge the gap between research and patient application.”

“eXmoor worked closely with our process development team to support our iPSC program as we successfully advanced from a very early stage to preclinical stage. Their expertise and collaborative approach made a real difference in working alongside our team, to address our unique scientific challenges.”

“I have had the pleasure of working with the eXmoor team for many years. Their experience and knowledge of facility design and manufacturing advanced therapy medicinal products is unparalleled. Their expertise and supportive approach made a real difference to our project, and we couldn’t have asked for a better partner.”

“The most important thing for us is to work in partnership with our consultants and eXmoor really feels like a vital part of the team. Their client focused and agile approach to project management has meant that we can trust and rely on them to deliver the very best advice and solutions to meet our needs.”

“We contracted eXmoor to rapidly perform a feasibility assessment on a potential expansion project we were interested in pursuing. The eXmoor team understood the business drivers for this approach and delivered a clear and well thought out package that really helped with our assessment of the opportunity.”

“eXmoor was an integral part of a collaborative partnership to design and deliver a world-leading industry development environment, with inherent flexibility, to develop and test innovative cell and gene therapy processes.”